HSR25-195: Risk of Venous and Arterial Thrombosis As Adverse Events in Patients Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Post-Market Analysis
"HSR25-195: Risk of Venous and Arterial Thrombosis As Adverse Events in Patients Receiving Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: A Post-Market Analysis" published on 28 Mar 2025 by National Comprehensive Cancer Network.
Authors
- Donglin Yan (ORCID: https://orcid.org/0000-0002-5111-9437)
- Zin Myint (ORCID: https://orcid.org/0000-0002-3479-4203)
- Megan Foley (ORCID: https://orcid.org/0000-0002-3201-7902)
- Kris Varothai
Institutions
- University of Kentucky (US)
- Markey Cancer Center (US)
Publication Details
- Journal
- Journal of the National Comprehensive Cancer Network
- Published
- 2025-03-28
- DOI
- https://doi.org/10.6004/jnccn.2024.7237
- Primary Topic
- Angiogenesis and VEGF in Cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00